Current Approaches for Phenotyping as a Target for Precision Medicine in COPD Management

References

• Barnes PJ, Burney PG, Silverman EK, Celli BR, Vestbo J, Wedzicha JA, Wouters EF. Chronic obstructive pulmonary disease. Nat Rev Dis Primers. 2015;1:15076. doi: 10.1038/nrdp.2015.76.
   PubMed Web of Science ®Google Scholar
• Beasley R, Weatherall M, Travers J, Shirtcliffe P. Time to define the disorders of the syndrome of COPD. Lancet. 2009;374(9691):670–672. doi:10.1016/S0140-6736(09)61541-5. PMID: 19716947.
   PubMed Web of Science ®Google Scholar
• Wouters EF, Wouters BB, Augustin IM, Franssen FM. Personalized medicine and chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2017;23(3):241–246. doi:10.1097/MCP.0000000000000377. PMID: 28257315.
   PubMed Web of Science ®Google Scholar
• Echazarreta AL, Arias SJ, Del Olmo R, Giugno ER, Colodenco FD, Arce SC, Bossio JC, Armando G, Soriano JB. Prevalence of COPD in 6 Urban Clusters in Argentina: the EPOC.AR study. Arch Bronconeumol. 2017. doi:10.1016/j.arbres.2017.09.018. PMID: 29221827.
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Ruiz-Ramos M, Soriano JB. Mortality trends in chronic obstructive pulmonary disease in Europe, 1994–2010: a joinpoint regression analysis. Lancet Respir Med. 2014;2(1):54–62. doi:10.1016/S2213-2600(13)70232-7. PMID: 24461902.
   PubMed Web of Science ®Google Scholar
• Collaborators GBDCRD. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. doi:10.1016/S2213-2600(17)30293-X. PMID: 28822787.
   PubMed Web of Science ®Google Scholar
• Soler-Cataluna JJ. Clinical practice guidelines or personalized medicine in chronic obstructive pulmonary disease? Arch Bronconeumol. 2017. doi:10.1016/j.arbres.2017.08.002.
   Web of Science ®Google Scholar
• Soler-Cataluna JJ, Sauleda J, Valdes L, Marin P, Aguero R, Perez M, Miravitlles M. Prevalence and perception of 24-hour symptom patterns in patients with stable chronic obstructive pulmonary disease in Spain. Arch Bronconeumol. 2016;52(6):308–315. doi:10.1016/j.arbr.2016.03.019. PMID: 26774700.
   PubMed Web of Science ®Google Scholar
• Kumar A, Kunal S, Shah A. Incidence and impact of upper airway symptoms in patients with chronic obstructive pulmonary disease. Arch Bronconeumol. 2017;53(11):647–649. doi:10.1016/j.arbres.2017.03.001. PMID: 28676253.
   PubMed Web of Science ®Google Scholar
• Anzueto A, Calverley PMA, Mueller A, Metzdorf N, Haensel M, Jardim JR, Pizzichini E, Giraldo H, Ramirez-Venegas A, Giugno ER. Demographic characteristics and clinical outcomes in patients from latin America versus the rest of the world: a TIOSPIR((R)) post-hoc analysis. Arch Bronconeumol. 2018. doi:10.1016/j.arbres.2017.11.010. PMID: 29317111.
   PubMed Web of Science ®Google Scholar
• Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT) scores. BMC Pulm Med. 2011;11:42. doi:10.1186/1471-2466-11-42. PMID: 21835018.
   PubMed Web of Science ®Google Scholar
• Feliz-Rodriguez D, Zudaire S, Carpio C, Martinez E, Gomez-Mendieta A, Santiago A, Alvarez-Sala R, Garcia-Rio F. Evolution of the COPD Assessment Test score during chronic obstructive pulmonary disease exacerbations: determinants and prognostic value. Can Respir J. 2013;20(5):e92–e97. doi:10.1155/2013/398120. PMID: 24093119.
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Nakamura H, Chubachi S, Sasaki M, Haraguchi M, Yoshida S, Tsuduki K, Shirahata T, Takahashi S, Minematsu N, Koh H, et al. Analysis of comorbid factors that increase the COPD assessment test scores. Respir Res. 2014;15:13. doi:10.1186/1465-9921-15-13. PMID: 24502760.
   PubMed Web of Science ®Google Scholar
• Dodd JW, Marns PL, Clark AL, Ingram KA, Fowler RP, Canavan JL, Patel MS, Kon SS, Hopkinson NS, Polkey MI, et al. The COPD Assessment Test (CAT): short- and medium-term response to pulmonary rehabilitation. COPD. 2012;9(4):390–394. doi:10.3109/15412555.2012.671869. PMID: 22497561.
   PubMedGoogle Scholar
• Kocks JW, Blom CM, Kasteleyn MJ, Oosterom W, Kollen BJ, Van der Molen T, Chavannes NH. Feasibility and applicability of the paper and electronic COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ) in primary care: a clinimetric study. NPJ Prim Care Respir Med. 2017;27(1):20. doi:10.1038/s41533-017-0023-0. PMID: 28352087.
   PubMedGoogle Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report: GOLD executive summary. Arch Bronconeumol. 2017;53(3):128–149. doi:10.1016/j.arbres.2017.02.001. PMID: 28274597.
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Fernandez-Villar A, Calero-Acuna C, Represas-Represas C, Lopez-Ramirez C, Fernandez VL, Soler-Cataluna JJ, Casamor R, On-Sint study group. Evaluation of the COPD Assessment Test and GOLD patient types: a cross-sectional analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:975–984. doi:10.2147/COPD.S82781. PMID: 26064045.
   PubMed Web of Science ®Google Scholar
• Rassouli F, Baty F, Stolz D, Albrich WC, Tamm M, Widmer S, Brutsche MH. Longitudinal change of COPD assessment test (CAT) in a telehealthcare cohort is associated with exacerbation risk. Int J Chron Obstruct Pulmon Dis. 2017;12:3103–3109. doi:10.2147/COPD.S141646. PMID: 29123387.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA, MacNee W, et al. Evaluation of COPD Longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J. 2008;31(4):869–873. doi:10.1183/09031936.00111707. PMID: 18216052.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184–1192. doi:10.1056/NEJMoa1105482.
   PubMed Web of Science ®Google Scholar
• Hansel TT, Barnes PJ. New drugs for exacerbations of chronic obstructive pulmonary disease. Lancet. 2009;374(9691):744–755. doi:10.1016/S0140-6736(09)61342-8. PMID: 19716967.
   PubMed Web of Science ®Google Scholar
• Decramer M, Celli B, Tashkin DP, Pauwels RA, Burkhart D, Cassino C, Kesten S. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD. 2004;1(2):303–312. doi:10.1081/COPD-200026934. PMID: 17136995.
   PubMedGoogle Scholar
• Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122. doi:10.1186/1465-9921-11-122. PMID: 20831787.
   PubMed Web of Science ®Google Scholar
• Hofstede SN, van Bodegom-Vos L, Kringos DS, Steyerberg E, Marang-van de Mheen PJ. Mortality, readmission and length of stay have different relationships using hospital-level versus patient-level data: an example of the ecological fallacy affecting hospital performance indicators. BMJ Qual Saf. 2017. doi:10.1136/bmjqs-2017-006776. PMID: 28986516.
   PubMed Web of Science ®Google Scholar
• Mullerova H, Lu C, Li H, Tabberer M. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS One. 2014;9(1):e85540. doi:10.1371/journal.pone.0085540. PMID: 24427316.
   PubMed Web of Science ®Google Scholar
• Boutou AK, Shrikrishna D, Tanner RJ, Smith C, Kelly JL, Ward SP, Polkey MI, Hopkinson NS. Lung function indices for predicting mortality in COPD. Eur Respir J. 2013;42(3):616–625. doi:10.1183/09031936.00146012. PMID: 23349449.
   PubMed Web of Science ®Google Scholar
• Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(6):591–597. doi:10.1164/rccm.200407-867OC. PMID: 15591470.
   PubMed Web of Science ®Google Scholar
• Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931. doi:10.1136/thx.2005.040527. PMID: 16055622.
   PubMed Web of Science ®Google Scholar
• Hospers JJ, Postma DS, Rijcken B, Weiss ST, Schouten JP. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet. 2000;356(9238):1313–1317. doi:10.1016/S0140-6736(00)02815-4. PMID: 11073020.
   PubMed Web of Science ®Google Scholar
• Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012. doi:10.1056/NEJMoa021322. PMID: 14999112.
   PubMed Web of Science ®Google Scholar
• Lahousse L, Seys LJM, Joos GF, Franco OH, Stricker BH, Brusselle GG. Epidemiology and impact of chronic bronchitis in chronic obstructive pulmonary disease. Eur Respir J. 2017;50(2): 1602470. doi:10.1183/13993003.02470-2016. PMID: 28798087.
   PubMed Web of Science ®Google Scholar
• Moy ML, Gould MK, Liu IA, Lee JS, Nguyen HQ. Physical activity assessed in routine care predicts mortality after a COPD hospitalisation. ERJ Open Res. 2016;2(1): 00062-2015. doi:10.1183/23120541.00062-2015. PMID: 27730174.
   PubMedGoogle Scholar
• Nishimura K, zumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121(5):1434–1440. doi:10.1378/chest.121.5.1434. PMID: 12006425.
   PubMed Web of Science ®Google Scholar
• Di Marco F, Milic-Emili J, Boveri B, Carlucci P, Santus P, Casanova F, Cazzola M, Centanni S. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J. 2003;21(1):86–94. doi:10.1183/09031936.03.00020102. PMID: 12570114.
   PubMed Web of Science ®Google Scholar
• Di Marco F, Sotgiu G, Santus P, O'Donnell DE, Beeh KM, Dore S, Roggi MA, Giuliani L, Blasi F, Centanni S. Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis. Respir Res. 2018;19(1):18. doi:10.1186/s12931-018-0721-3. PMID: 29368604.
   PubMed Web of Science ®Google Scholar
• Santus P, Radovanovic D, Di Marco F, Raccanelli R, Valenti V, Centanni S. Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study. Pulm Pharmacol Ther. 2015;35:42–49. doi:10.1016/j.pupt.2015.11.001.
   PubMed Web of Science ®Google Scholar
• Santus P, Radovanovic D, Di Marco S, Valenti V, Raccanelli R, Blasi F, Centanni S, Bussotti M. Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial. Int J Chron Obstruct Pulmon Dis. 2015;10:1917–1923. doi:10.2147/COPD.S91684. PMID: 26392766.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Burgel PR, Franssen FME, Lopez-Campos JL, Loukides S, Hurst JR, Flezar M, Ulrik CS, Di Marco F, Stolz D, et al. How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2017;196(2):139–149. doi:10.1164/rccm.201609-1794CI. PMID: 27922741.
   PubMed Web of Science ®Google Scholar
• Toledo-Pons N, Cosio BG. Is there room for theophylline in COPD? Arch Bronconeumol. 2017;53(10):539–540. doi:10.1016/j.arbres.2017.05.022. PMID: 28645434.
   PubMed Web of Science ®Google Scholar
• Gea J. The future of biological therapies in COPD. Arch Bronconeumol. 2017. doi:10.1016/j.arbres.2017.11.004.
   Web of Science ®Google Scholar
• Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(9):926–934. doi:10.1164/rccm.200607-995OC. PMID: 17290043.
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Sethi S, Dawson M, Ward CK, Finch DK, Penney M, Newbold P, van der Merwe R. A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease. Respir Res. 2017;18(1):153. doi:10.1186/s12931-017-0633-7. PMID: 28793896.
   PubMed Web of Science ®Google Scholar
• Nordenmark LH, Taylor R, Jorup C. Feasibility of computed tomography in a multicenter COPD trial: a study of the effect of AZD9668 on structural airway changes. Adv Ther. 2015;32(6):548–566. doi:10.1007/s12325-015-0215-3. PMID: 26043724.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, Martinot JB, Sagara H, Albers FC, Bradford ES, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377(17):1613–1629. doi:10.1056/NEJMoa1708208. PMID: 28893134.
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Marquez-Martin E, Ortega-Ruiz F. Triple therapy vs. triple therapy in COPD. Arch Bronconeumol. 2017;53(8):419–420. doi:10.1016/j.arbres.2017.01.020.
   PubMed Web of Science ®Google Scholar
• Singh D, Papi A, Corradi M, Pavlisova I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973. doi:10.1016/S0140-6736(16)31354-X. PMID: 27598678.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446. doi:10.1164/rccm.201703-0449OC. PMID: 28375647.
   PubMed Web of Science ®Google Scholar
• Alcazar-Navarrete B, Castellano Minan F, Romero Palacios PJ. The future of triple therapy in chronic obstructive pulmonary disease. Arch Bronconeumol. 2018;54(2):63–64. doi:10.1016/j.arbres.2017.06.019. PMID: 28495073.
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Calero-Acuna C, Marquez-Martin E, Quintana Gallego E, Carrasco-Hernandez L, Abad Arranz M, Ortega Ruiz F. Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review. Int J Chron Obstruct Pulmon Dis. 2017;12:1867–1876. doi:10.2147/COPD.S132962. PMID: 28694697.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Singh D, Munzu C, Kilbride S, Church A. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trials. Respir Med. 2016;112:65–74. doi:10.1016/j.rmed.2016.01.001. PMID: 26797016.
   PubMed Web of Science ®Google Scholar
• Garcia-Aymerich J. Physical activity in chronic obstructive pulmonary disease. an update. Arch Bronconeumol. 2017;53(8):413–414. doi:10.1016/j.arbres.2016.11.011.
   PubMed Web of Science ®Google Scholar
• Cebollero P, Anton M, Hernandez M, Hueto J. Walking program for COPD patients: clinical impact after two years of follow-up. Arch Bronconeumol. 2017. doi:10.1016/j.arbres.2017.11.002. PMID: 29248261.
   PubMed Web of Science ®Google Scholar
• Pleguezuelos E, Guirao L, Moreno E, Samitier B, Ortega P, Vila X, Majo M, Gonzalez MV, Ovejero L, Juanola J, Gomez A, et al. Safety of Rehabilitation Program for COPD Patients. Arch Bronconeumol. 2018;54(2):111–112. doi:10.1016/j.arbres.2017.06.012. PMID: 28789812.
   PubMed Web of Science ®Google Scholar
• Frandin K, Gronstedt H, Helbostad JL, Bergland A, Andresen M, Puggaard L, Harms-Ringdahl K, Granbo R, Hellstrom K. Long-term effects of individually tailored physical training and activity on physical function, well-being and cognition in Scandinavian nursing home residents: a randomized controlled trial. Gerontology. 2016;62(6):571–580. doi:10.1159/000443611. PMID: 26963569.
   PubMed Web of Science ®Google Scholar
• Bettoncelli G, Blasi F, Brusasco V, Centanni S, Corrado A, De Benedetto F, De Michele F, Di Maria GU, Donner CF, Falcone F, et al. The clinical and integrated management of COPD. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31 (Suppl 1):3–21. PMID: 24820963.
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global initiative for chronic obstructive lung disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163(5):1256–1276. doi:10.1164/ajrccm.163.5.2101039. PMID: 11316667.
   PubMedGoogle Scholar
• Lopez-Campos JL. [Treatment strategies in chronic obstructive pulmonary disease: a proposal for standardization]. Arch Bronconeumol. 2010;46(12):617–620. doi:10.1016/S1579-2129(10)70135-X. PMID: 20624667.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Roisin R, Agusti A. The GOLD initiative 2011: a change of paradigm? Arch Bronconeumol. 2012;48(8):286–289. doi:10.1016/j.arbres.2012.02.018. PMID: 22537593.
   PubMed Web of Science ®Google Scholar
• Soler-Cataluna JJ, Alcazar-Navarrete B, Miravitlles M. The concept of control of COPD in clinical practice. Int J Chron Obstruct Pulmon Dis. 2014;9:1397–1405. doi:10.2147/COPD.S71370. PMID: 25548521.
   PubMed Web of Science ®Google Scholar
• Duarte Araujo A, Hespanhol V, Correia-de-Sousa J. Is COPD control a useful concept? Assessing treatment success by evaluating COPD-related health status. Arch Bronconeumol. 2017;53(9):530–531. doi:10.1016/j.arbr.2017.01.012. PMID: 28126197.
   PubMed Web of Science ®Google Scholar
• Montes de Oca M, Lopez Varela MV, Laucho-Contreras ME, Casas A, Schiavi E, Rey A, Silva A, en nombre del equipo del estudio P. Classification of patients with chronic obstructive pulmonary disease according to the Latin American Thoracic Association (ALAT) staging systems and the global initiative for chronic obstructive pulmonary disease (GOLD). Arch Bronconeumol. 2017;53(3):98–106. doi:10.1016/j.arbres.2016.08.015. PMID: 27956034.
   PubMed Web of Science ®Google Scholar
• Jones PW, Adamek L, Nadeau G, Banik N. Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification. Eur Respir J. 2013;42(3):647–654. doi:10.1183/09031936.00125612. PMID: 23258783.
   PubMed Web of Science ®Google Scholar
• Smid DE, Franssen FME, Gonik M, Miravitlles M, Casanova C, Cosio BG, de Lucas-Ramos P, Marin JM, Martinez C, Mir I, et al. Redefining cut-points for high symptom burden of the global initiative for chronic obstructive lung disease classification in 18,577 patients with chronic obstructive pulmonary disease. J Am Med Dir Assoc. 2017;18(12): 1097.e11–e24. doi:10.1016/j.jamda.2017.09.003.
   Web of Science ®Google Scholar
• Blasi F, Neri L, Centanni S, Falcone F, Di Maria G. Clinical characterization and treatment patterns for the frequent exacerbator phenotype in chronic obstructive pulmonary disease with severe or very severe airflow limitation. COPD. 2017;14(1):15–22. doi:10.1080/15412555.2016.1232380. PMID: 27824270.
   PubMedGoogle Scholar
• Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa0909883. PMID: 20843247.
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Calero-Acuna C, Marquez-Martin E. Frequent or persistent exacerbations: identifying the real problem. Arch Bronconeumol. 2016;52(12):577–578. doi:10.1016/j.arbres.2016.05.019. PMID: 27374282.
   PubMed Web of Science ®Google Scholar
• Cabrera Lopez C, Casanova Macario C, Marin Trigo JM, de-Torres JP, Sicilia Torres R, Gonzalez JM, Polverino F, Divo M, Pinto Plata V, Zulueta JJ, et al. Comparison of 2017 and 2015 Global Initiative for Obstructive Lung Disease: impact on grouping and outcomes. Am J Respir Crit Care Med. 2018;197(4):463–469. doi:10.1164/rccm.201707-1363OC.
   PubMed Web of Science ®Google Scholar
• Marin JM, Carrizo SJ, Casanova C, Martinez-Camblor P, Soriano JB, Agusti AG, Celli BR. Prediction of risk of COPD exacerbations by the BODE index. Respir Med. 2009;103(3):373–378. doi:10.1016/j.rmed.2008.10.004. PMID: 19013781.
   PubMed Web of Science ®Google Scholar
• Marin JM, Cote CG, Diaz O, Lisboa C, Casanova C, Lopez MV, Carrizo SJ, Pinto-Plata V, Dordelly LJ, Nekach H, et al. Prognostic assessment in COPD: health related quality of life and the BODE index. Respir Med. 2011;105(6):916–921. doi:10.1016/j.rmed.2011.01.007. PMID: 21282050.
   PubMed Web of Science ®Google Scholar
• Mantoani LC, Hernandes NA, Guimaraes MM, Vitorasso RL, Probst VS, Pitta F. Does the BODE index reflect the level of physical activity in daily life in patients with COPD? Rev Bras Fisioter. 2011;15(2):131–137. doi:10.1590/S1413-35552011000200008. PMID: 21789363.
   PubMedGoogle Scholar
• Funk GC, Kirchheiner K, Burghuber OC, Hartl S. BODE index versus GOLD classification for explaining anxious and depressive symptoms in patients with COPD—a cross-sectional study. Respir Res. 2009;10:1. doi:10.1186/1465-9921-10-1. PMID: 19134192.
   PubMed Web of Science ®Google Scholar
• Marin JM, Alfageme I, Almagro P, Casanova C, Esteban C, Soler-Cataluna JJ, de Torres JP, Martinez-Camblor P, Miravitlles M, Celli BR, et al. Multicomponent indices to predict survival in COPD: the COCOMICS study. Eur Respir J. 2013;42(2):323–332. doi:10.1183/09031936.00121012. PMID: 23222874.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluna JJ, Calle M, Molina J, Almagro P, Quintano JA, Riesco JA, Trigueros JA, Pinera P, Simon A, et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish society of pulmonology and thoracic surgery. Arch Bronconeumol. 2012;48(7):247–257. doi:10.1016/j.arbres.2012.04.001.
   PubMed Web of Science ®Google Scholar
• Calle Rubio M, Alcazar Navarrete B, Soriano JB, Soler-Cataluna JJ, Rodriguez Gonzalez-Moro JM, Fuentes Ferrer ME, Lopez-Campos JL. Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study. Int J Chron Obstruct Pulmon Dis. 2017;12:417–426. doi:10.2147/COPD.S124482. PMID: 28182155.
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Abad Arranz M, Calero-Acuna C, Romero-Valero F, Ayerbe-Garcia R, Hidalgo-Molina A, Aguilar-Perez-Grovas RI, Garcia-Gil F, Casas-Maldonado F, Caballero-Ballesteros L, et al. Guideline adherence in outpatient clinics for chronic obstructive pulmonary disease: results from a clinical audit. PLoS One. 2016;11(3):e0151896. doi:10.1371/journal.pone.0151896. PMID: 26985822.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluna JJ, Calle M, Molina J, Almagro P, Quintano JA, Trigueros JA, Cosio BG, Casanova C, Antonio Riesco J, et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017. Pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53(6):324–335. doi:10.1016/j.arbres.2017.03.018. PMID: 28477954.
   PubMed Web of Science ®Google Scholar
• Burrows B, Niden AH, Fletcher CM, Jones NL. Clinical types of chronic obstructive lung disease in London and in Chicago. A study of one hundred patients. Am Rev Respir Dis. 1964;90:14–27. doi:10.1164/arrd.1964.90.1.14. PMID: 14178622.
   PubMed Web of Science ®Google Scholar
• Terminology, Definitions, and Classification of Chronic Pulmonary Emphysema and Related Conditions. Thorax. 1959;14(4):286–99. doi:10.1136/thx.14.4.286.
   Google Scholar
• Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598–604. doi:10.1164/rccm.200912-1843CC. PMID: 20522794.
   PubMed Web of Science ®Google Scholar
• Shirtcliffe P, Weatherall M, Travers J, Beasley R. The multiple dimensions of airways disease: targeting treatment to clinical phenotypes. Curr Opin Pulm Med. 2011;17(2):72–78. doi:10.1097/MCP.0b013e328341f181. PMID: 21150622.
   PubMed Web of Science ®Google Scholar
• Fernandez-Villar A, Lopez-Campos JL. Mixed COPD-asthma phenotype: ACOS or CAOS? A reflection on recent guidelines and recommendations. Arch Bronconeumol. 2016;52(5):277–278. doi:10.1016/j.arbr.2016.03.002. PMID: 26299441.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluna JJ, Calle M, Molina J, Almagro P, Quintano JA, Riesco JA, Trigueros JA, Pinera P, Simon A, et al. Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol. 2014;50(Suppl 1):1–16. doi:10.1016/S0300-2896(14)70070-5. PMID: 24507959.
   PubMed Web of Science ®Google Scholar
• Plaza V, Alvarez F, Calle M, Casanova C, Cosio BG, Lopez-Vina A, Perez de Llano L, Quirce S, Roman-Rodriguez M, Soler-Cataluna JJ, et al. Consensus on the Asthma-COPD Overlap Syndrome (ACOS) between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA). Arch Bronconeumol. 2017;53(8):443–449. doi:10.1016/j.arbres.2017.04.002. PMID: 28495077.
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, Maiz L, Olveira C, Giron RM, de la Rosa D, Blanco M, Canton R, Vendrell M, Polverino E, de Gracia J, et al. Spanish guidelines on the evaluation and diagnosis of bronchiectasis in adults. Arch Bronconeumol. 2018;54(2):79–87. doi:10.1016/j.arbres.2017.07.015.
   PubMed Web of Science ®Google Scholar
• Carrion Valero F, Paulos Dos Santos S, Celli BR. Smoking In COPD Patients: a new clinical phenotype? Arch Bronconeumol. 2017. doi:10.1016/j.arbres.2017.10.021. PMID: 29217210.
   PubMed Web of Science ®Google Scholar
• Perez de Llano L, Cosio BG, Miravitlles M, Plaza V, CHACOS study group. Accuracy of a new algorithm to identify asthma-COPD Overlap (ACO) patients in a cohort of patients with chronic obstructive airway disease. Arch Bronconeumol. 2017. doi:10.1016/j.arbres.2017.10.007.
   Web of Science ®Google Scholar
• Alcazar-Navarrete B, Castellano Minan F, Romero Palacios PJ. Clinical guidelines in asthma and chronic obstructive pulmonary disease: how useful are they in clinical practice? Arch Bronconeumol. 2018;54(3):117–118. doi:10.1016/j.arbres.2017.07.021. PMID: 28495073.
   PubMed Web of Science ®Google Scholar
• Baloira Villar A, Palop Cervera M. Does the exacerbator phenotype in chronic obstructive pulmonary disease really exist? Arch Bronconeumol. 2018;54(3):119–120. doi:10.1016/j.arbres.2017.07.024. PMID: 28477953.
   PubMed Web of Science ®Google Scholar
• Baloira A, Blanco N. Non-exacerbator phenotype in chronic obstructive pulmonary disease: Should we go a little further? Arch Bronconeumol. 2017;53(10):537–538. doi:10.1016/j.arbres.2017.03.013. PMID: 28477953.
   PubMed Web of Science ®Google Scholar
• Agusti A. The path to personalised medicine in COPD. Thorax. 2014;69(9):857–864. doi:10.1136/thoraxjnl-2014-205507. PMID: 24781218.
   PubMed Web of Science ®Google Scholar
• Kang J, Kim KT, Lee JH, Kim EK, Kim TH, Yoo KH, Lee JS, Kim WJ, Kim JH, Oh YM. Predicting treatable traits for long-acting bronchodilators in patients with stable COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:3557–3565. doi:10.2147/COPD.S151909. PMID: 29263660.
   PubMed Web of Science ®Google Scholar
• Jareno-Esteban JJ, Munoz-Lucas MA, Gomez-Martin O, Utrilla-Trigo S, Gutierrez-Ortega C, Aguilar-Ros A, Collado-Yurrita L, Callol-Sanchez LM. Study of 5 volatile organic compounds in exhaled breath in chronic obstructive pulmonary disease. Arch Bronconeumol. 2017;53(5):251–256. doi:10.1016/j.arbr.2017.03.007. PMID: 27780574.
   PubMed Web of Science ®Google Scholar
• Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010;137(6):1410–1416. doi:10.1378/chest.09-1850. PMID: 20525651.
   PubMed Web of Science ®Google Scholar